以病理细胞或炎症为特征的异常细胞微环境是各种癌症类型的额外危险因素。虽然慢性炎症在大多数弥漫性肿瘤发展中的重要性已被广泛研究，但软骨肉瘤的分析存在例外。软骨肉瘤占所有骨肉瘤的 20-30%，估计全球发病率为十万分之一。诊断时的平均年龄为 50 岁，超过 70% 的患者年龄超过 40 岁。这项回顾性研究旨在探讨 C 反应蛋白 (CRP) 作为与软骨肉瘤组织病理学结果相关的预后因素的作用。该研究纳入了 70 名在 2004 年至 2019 年间被诊断患有软骨肉瘤并接受治疗的患者。术前 CRP 水平以 mg/dL 为单位测量，非病理值定义为低于 0.5 mg/dL。无病生存时间是从最初诊断到局部复发或转移等事件计算的。随访状态分为疾病死亡、无疾病证据或患病存活。如果患者的实验室值不足、随访信息缺失或组织病理学报告不完整，则被排除在外。对于 CRP 水平 > 0.5 mg/dL 的患者，减少随访时间的计算风险估计高出 2.25 倍（HR 2.25 和 95% CI 1.13-4.45），肿瘤大小 > pT2 的患者则高出 3 倍（HR 3 和 95% CI 1.59-5.92）。我们可以很容易地确认，软骨肉瘤的高分级、术前病理CRP水平和大小> 8 cm是预后降低的危险因素。治疗前CRP值大于0.5 mg/dL可以被认为是远处转移的敏感预后和危险因素。软骨肉瘤患者的转移。

An aberrant cellular microenvironment characterized by pathological cells or inflammation represents an added risk factor across various cancer types. While the significance of chronic inflammation in the development of most diffuse tumors has been extensively studied, an exception to this analysis exists in the context of chondrosarcomas. Chondrosarcomas account for 20-30% of all bone sarcomas, with an estimated global incidence of 1 in 100,000. The average age at diagnosis is 50, and over 70% of patients are over 40. This retrospective study aimed to examine the role of C-reactive protein (CRP) as a prognostic factor in relation to the histopathological findings in chondrosarcoma.In this retrospective study, 70 patients diagnosed with chondrosarcoma and treated between 2004 and 2019 were included. Preoperative CRP levels were measured in mg/dL, with non-pathological values defined as below 0.5 mg/dL. Disease-free survival time was calculated from the initial diagnosis to events such as local recurrence or metastasis. Follow-up status was categorized as death from disease, no evidence of disease, or alive with disease. Patients were excluded if they had insufficient laboratory values, missing follow-up information, or incomplete histopathological reports.The calculated risk estimation of a reduced follow-up time was 2.25 timed higher in the patients with a CRP level >0.5 mg/dL (HR 2.25 and 95% CI 1.13-4.45) and 3 times higher in patients with a tumor size > pT2 (HR 3 and 95% CI 1.59-5.92). We can easily confirm that risk factors for reduced prognosis lie in chondrosarcoma high grading, preoperative pathological CRP- level, and a size > 8 cm.A pretreatment CRP value greater than 0.5 mg/dL can be considered a sensitive prognostic and risk factor for distant metastasis for chondrosarcoma patients.